Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 6/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 2/20 | 0.39 |
| ▸ | ANPEP | P15144 | 2/20 | 0.39 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3593496 | 0.88 | RORC (0.41) | RORCTDP1HSD11B1MEN1KMT2A | |
| SCHEMBL3588564 | 0.85 | LMNA (0.47) | HSD11B1MEN1KMT2AMMP2ANPEP | |
| SCHEMBL927334 | 0.75 | RORC (0.49) | RORCHSD11B1MEN1KMT2ANR1I2 | |
| SCHEMBL4843331 | 0.75 | TDP1 (0.47) | TDP1KMT2AMMP2LMNA | |
| SCHEMBL926563 | 0.72 | NPSR1 (0.48) | TDP1MEN1KMT2AMMP2ANPEP | |
| SCHEMBL23630340 | 0.72 | KMT2A (0.56) | HSD11B1MEN1KMT2AMMP2ANPEP | |
| SCHEMBL926085 | 0.72 | LMNA (0.50) | TDP1HSD11B1MEN1KMT2ALMNA | |
| SCHEMBL3591921 | 0.72 | LMNA (0.50) | TDP1HSD11B1MEN1KMT2ALMNA | |
| SCHEMBL2519677 | 0.72 | ESR1 (0.56) | TDP1MEN1KMT2ARECQLMMP2 | |
| SCHEMBL2519672 | 0.72 | ESR1 (0.56) | TDP1MEN1KMT2ARECQLMMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7781481-B2 | N-arylsulfonyl-2,3-dihydro-1H-indoles and the use thereof as CCR9 inhibitors | NOVARTIS AG (CH) | 2010-08-24 | — | — | US | claimed |
| US-20080269312-A1 | Inhibitors of Ccr9 Activity | NOVARTIS AG (CH) | 2008-10-30 | — | — | US | claimed |
| EP-1968939-A2 | INHIBITORS OF CCR9 ACTIVITY | Novartis AG (CH) | 2008-09-17 | — | — | EP | claimed |
| WO-2007071442-A2 | INHIBITORS OF CCR9 ACTIVITY | NOVARTIS AG (CH) | 2007-06-28 | — | — | WO | claimed |
| US-7781481-B2 | N-arylsulfonyl-2,3-dihydro-1H-indoles and the use thereof as CCR9 inhibitors | NOVARTIS AG (CH) | 2010-08-24 | — | — | US | disclosed |
| US-20080269312-A1 | Inhibitors of Ccr9 Activity | NOVARTIS AG (CH) | 2008-10-30 | — | — | US | disclosed |
| EP-1968939-A2 | INHIBITORS OF CCR9 ACTIVITY | Novartis AG (CH) | 2008-09-17 | — | — | EP | disclosed |
| WO-2007071442-A2 | INHIBITORS OF CCR9 ACTIVITY | NOVARTIS AG (CH) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269312-A1 | Inhibitors of Ccr9 Activity | CCR9, CCR1, CCR4 | RORC 191/4885TDP1 1946/4885HSD11B1 1831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.